Author:
Deng Guanghui,Li Junjie,Huang Manping,Li Yunjia,Shi Hao,Wu Chaofeng,Zhao Jiamin,Qin Mengchen,Liu Chang,Yang Menghan,Wang Yunqing,Zhang Yuxue,Liao Yuxin,Zhou Chuying,Yang Jian,Xu Yunsheng,Liu Bin,Gao Lei
Funder
National Natural Science Foundation of China
Subject
Drug Discovery,Pharmacology
Reference39 articles.
1. Retracted: an ErChen and YinChen decoction ameliorates high-fat-induced nonalcoholic steatohepatitis in rats by regulating JNK1 signaling pathway;Alternative Medicine;Evid. Base Compl. Alternat. Med. 2019,2019
2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk;Athyros;Expert. Panel Statement Metabol.,2017
3. Lipogenesis inhibitors: therapeutic opportunities and challenges;Batchuluun;Nat. Rev. Drug Discov.,2022
4. Molecular pathways of nonalcoholic fatty liver disease development and progression;Bessone;Cell. Mol. Life Sci.,2019
5. Nonalcoholic fatty liver disease 2020: the state of the disease;Cotter;Gastroenterology,2020